IL6 and major depressive disorder: Blocking IL-6R-mediated pathways (e.g., tocilizumab) or neutralizing IL-6 function (e.g., sirukumab) might have clinical value in a subset of MDD patients, especially in treatment-resistant cases or in patients with peripheral inflammatory diseases (101).